Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
David S. Ettinger, Douglas E. Wood, Dara L. Aisner et al. · Journal of the National Comprehensive Cancer Network · 2022
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. Patients with metastatic lung cancer who are eligible for targeted therapies or immunotherapies are now surviving longer. This selection from the NCCN Guidelines for NSCLC focuses on targeted therapies for patients with metastatic NSCLC and actionable mutations.
Cited by 1,392 works. doi:10.6004/jnccn.2022.0025
Authors
- David S. Ettinger
- Douglas E. Wood
- Dara L. Aisner
- Wallace Akerley
- Jessica Ruth Bauman
- Ankit Bharat
- Débora S. Bruno
- Joe Yujiao Chang
- Lucian R. Chirieac
- Thomas Anthony D’Amico
- Malcolm M. DeCamp
- Thomas J. Dilling
- Jonathan E. Dowell
- Scott N. Gettinger
- Travis Edward Grotz
- Matthew A. Gubens
- Aparna Madhukeshwar Hegde
- Rudy P. Lackner
- Michael D. Lanuti
- Jules Lin
References
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Cancer statistics, 2022
- Cancer Statistics, 2021
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer